Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpelisib plus fulvestrant in Japanese patients with PIK3CA-mutant HR-positive, HER2-negative advanced breast cancer after aromatase inhibitor treatment
jRCT2080225342Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of alpelisib and fulvestrant in breast cancer (5 arms), sponsored by Novartis. Started Aug 2020; status: completed.
02
Drugs
alpelisibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080225342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225342.